Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung : Predictive factors for completion of treatment.

Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung cancer:Predictive factors for completion of treatment.

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000043437

Acronym

CARBOTAX

Enrollment

Registered

2007-01-12

Start date

2004-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This trial aims to determine the effiacy and toxicity of a standard treatment approach to locally advanced NSCLC in NSW and to examine potential predictors of treatment tolerability.

Interventions

6 cycles of weekly carboplatin and paclitaxel , concurrent radiotherapy and either induction or consolidation carboplatin and paclitaxel (2 x 3 weekly cycles). This is a complex protocol with dosages changing according to whether the patient is receiving concurrent treatment it is not practical to give the doses of every drug at every time. The mode of administration for each drug is intravenous. There is no control group.

Study design

Allocation

Non-randomised trial

Intervention model

Other

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

17 Years to No maximum

Healthy volunteers

Inclusion criteria

Stage IIIA/B histologically proven NSCLC. ECOG Performance Status 0 or1. Weight loss < 10% compared to original (pre-diagnosis) weight. FeV1 (Forced Expiratory volume 1 second) > 1.0L. Adequate hematological and biochemical reserve.

Exclusion criteria

Glomerular Filtration Rate (GFR) < 50ml/min (Cockroft-Gault formula). Prior chemotherapy or irradiation. Prior diagnosis of invasive cancer within the last 2 years. Symptomatic sensory or motor neuropathy. Contraindications to steroids. Pregnant or breastfeeding mothers. Intercurrent medical illnesses precluding combined modality therapy (except with clinician's authorisation).

Outcome results